Clinical trial
A Prospective, Multi-center, Randomized Parallel Controlled Clinical Study on the Efficacy and Safety of Protein A Immunoadsorption and Intravenous Immunoglobulin in the Treatment of Guillain-Barre Syndrome
NCT05114941 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhengzhou University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multi-center, Randomized Parallel Controlled Clinical Study on the Efficacy and Safety of Protein A Immunoadsorption and Intravenous Immunoglobulin in the Treatment of Guillain-Barre Syndrome
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou University
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- January 1, 2026
- Completion date
- December 31, 2026
- Enrollment
- 204 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.